These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 11486242)

  • 1. Anti-ischemic action of estrogen-progestogen continuous combined hormone replacement therapy in postmenopausal women with established angina pectoris: a randomized, placebo-controlled, double-blind, parallel-group trial.
    Sanderson JE; Haines CJ; Yeung L; Yip GW; Tang K; Yim SF; Jorgensen LN; Woo J
    J Cardiovasc Pharmacol; 2001 Sep; 38(3):372-83. PubMed ID: 11486242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of continuous combined hormone replacement therapy on arterial reactivity in postmenopausal women with established angina pectoris.
    Haines CJ; Yim SF; Sanderson JE
    Atherosclerosis; 2001 Dec; 159(2):467-70. PubMed ID: 11730828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of sequential combined oral 17beta-estradiol norethisterone acetate on insulin sensitivity and body composition in healthy postmenopausal women: a randomized single blind placebo-controlled study.
    Walker RJ; Lewis-Barned NJ; Sutherland WH; Goulding A; Edwards EA; de Jong SA; Gold E; Walker HL
    Menopause; 2001; 8(1):27-32. PubMed ID: 11201511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects on the androgen status of postmenopausal women treated with tibolone and continuous combined estradiol and norethindrone acetate replacement therapy.
    Dören M; Rübig A; Coelingh Bennink HJ; Holzgreve W
    Fertil Steril; 2001 Mar; 75(3):554-9. PubMed ID: 11239541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of combined oral estrogen/progestogen preparation (Kliogest) on bone mineral density, plasma lipids and postmenopausal symptoms in HRT-naïve Thai women.
    Jirapinyo M; Theppisai U; Manonai J; Suchartwatnachai C; Jorgensen LN
    Acta Obstet Gynecol Scand; 2003 Sep; 82(9):857-66. PubMed ID: 12911449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris. Ranolazine Study Group.
    Thadani U; Ezekowitz M; Fenney L; Chiang YK
    Circulation; 1994 Aug; 90(2):726-34. PubMed ID: 8044941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in lipid and lipoprotein profile in postmenopausal women receiving low-dose combinations of 17beta-estradiol and norethisterone acetate.
    Samsioe G; Li C; Borgfeldt C; Wilawan K; Aberg A; Larsen S
    Menopause; 2002; 9(5):335-42. PubMed ID: 12218722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trial of effect of transdermal continuous combined hormone replacement therapy on cardiovascular risk markers.
    Stevenson JC; Oladipo A; Manassiev N; Whitehead MI; Guilford S; Proudler AJ
    Br J Haematol; 2004 Mar; 124(6):802-8. PubMed ID: 15009069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A placebo-controlled trial of long-term oral combined continuous hormone replacement therapy in postmenopausal women: effects on arterial compliance and endothelial function.
    Teede HJ; Liang YL; Kotsopoulos D; Zoungas S; Cravent R; McGrath BP
    Clin Endocrinol (Oxf); 2001 Nov; 55(5):673-82. PubMed ID: 11894980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo-controlled study.
    Morabito N; Crisafulli A; Vergara C; Gaudio A; Lasco A; Frisina N; D'Anna R; Corrado F; Pizzoleo MA; Cincotta M; Altavilla D; Ientile R; Squadrito F
    J Bone Miner Res; 2002 Oct; 17(10):1904-12. PubMed ID: 12369794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of continuous combined estradiol-norethisterone acetate preparations on insulin sensitivity in postmenopausal nondiabetic women.
    Kimmerle R; Heinemann L; Heise T; Bender R; Weyer C; Hirschberger S; Berger M
    Menopause; 1999; 6(1):36-42. PubMed ID: 10100178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of continuous estrogen and estrogen-progestin replacement regimens on cardiovascular risk markers in postmenopausal women.
    Davidson MH; Maki KC; Marx P; Maki AC; Cyrowski MS; Nanavati N; Arce JC
    Arch Intern Med; 2000 Nov; 160(21):3315-25. PubMed ID: 11088095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of levormeloxifene in the prevention of postmenopausal bone loss and on the lipid profile compared to low dose hormone replacement therapy.
    Alexandersen P; Riis BJ; Stakkestad JA; Delmas PD; Christiansen C
    J Clin Endocrinol Metab; 2001 Feb; 86(2):755-60. PubMed ID: 11158042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, placebo-controlled trial of the effects of continuous combined hormone replacement therapy on coagulation and fibrinolytic systems in healthy postmenopausal women.
    Salobir BG; Keber I; Vrabic L
    Fertil Steril; 2002 Dec; 78(6):1178-83. PubMed ID: 12477508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the gonadotropin-releasing hormone agonist goserelin acetate alone versus goserelin combined with estrogen-progestogen add-back therapy in the treatment of endometriosis.
    Kiilholma P; Tuimala R; Kivinen S; Korhonen M; Hagman E
    Fertil Steril; 1995 Nov; 64(5):903-8. PubMed ID: 7589632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hormone replacement therapy does not affect the 24-hour heart rate variability in postmenopausal women: results of a randomized, placebo-controlled trial with two regimens.
    Fernandes EO; Moraes RS; Ferlin EL; Wender MC; Ribeiro JP
    Pacing Clin Electrophysiol; 2005 Jan; 28 Suppl 1():S172-7. PubMed ID: 15683490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids.
    Rozenberg S; Ylikorkala O; Arrenbrecht S
    Int J Fertil Womens Med; 1997; 42 Suppl 2():376-87. PubMed ID: 9397385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positive effects on cardiovascular and breast metabolic markers of oral estradiol and dydrogesterone in comparison with transdermal estradiol and norethisterone acetate.
    Campagnoli C; Colombo P; De Aloysio D; Gambacciani M; Grazioli I; Nappi C; Serra GB; Genazzani AR
    Maturitas; 2002 Apr; 41(4):299-311. PubMed ID: 12034517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects on serum lipid and leptin levels of three different doses of norethisterone continuously combined with a fixed dose of 17beta-estradiol for nasal administration in postmenopausal women: a controlled, double-blind study.
    Castelo-Branco C; Palacios S; Vázquez F; Villero J; Ferrer J; Ascaso C; Balasch J
    Fertil Steril; 2007 Aug; 88(2):383-9. PubMed ID: 17561009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density.
    Lundström E; Christow A; Kersemaekers W; Svane G; Azavedo E; Söderqvist G; Mol-Arts M; Barkfeldt J; von Schoultz B
    Am J Obstet Gynecol; 2002 Apr; 186(4):717-22. PubMed ID: 11967497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.